Item request has been placed!

Item request cannot be made.

Processing Request

نتائج البحث

Display Settings

النتائج لكل صفحة: 10

Sort By: Relevance

Filter

فلترة النتائج

Content Provider : Academic Search Ultimate

إعادة تعيين خيارات الفبترة

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

The proteasome inhibitor ixazomib targets epigenetic chromatin modification enzymes upregulated by m2c macrophage polarisation in lung cancer.

Authors : Tilki, Elif Kaya¹ ; Öztürk, Selin Engür²

Source: Istanbul Journal of Pharmacy. Aug2024, Vol. 54 Issue 2, p215-222. 8p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

伊沙佐米治疗复发 / 难治性多发性骨髓瘤的疗效和安全性的系统评价.

Authors : 李芸¹ ; 李兵胜²; 李义秀¹

Source: Evaluation & Analysis of Drug-Use in Hospitals of China. 2024, Vol. 24 Issue 4, p473-477. 5p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.

Authors : Partanen, Anu¹ (AUTHOR) ; Waage, Anders² (AUTHOR) ; Peceliunas, Valdas³ (AUTHOR)

Source: Cancers. Mar2024, Vol. 16 Issue 5, p1024. 15p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.

Authors : Furlan, Anna¹ (AUTHOR) ; Cea, Michele² (AUTHOR); Pavan, Laura³ (AUTHOR)

Source: Cancer Medicine. Apr2024, Vol. 13 Issue 7, p1-14. 14p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Assessment of prolonged proteasome inhibition through ixazomib‐based oral regimen on newly diagnosed and first‐relapsed multiple myeloma: A real‐world Chinese cohort study.

Authors : Liu, Aijun¹ (AUTHOR); Yu, Hong² (AUTHOR); Hou, Rui³ (AUTHOR)

Source: Cancer Medicine. May2024, Vol. 13 Issue 9, p1-10. 10p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.

Authors : DerSarkissian, Maral¹ (AUTHOR) ; Cranmer, Holly² (AUTHOR); Dabora, Jonathan³ (AUTHOR)

Source: Hematology. Dec2023, Vol. 28 Issue 1, p1-10. 10p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma.

Authors : Bühler, Selina¹ (AUTHOR); Akhoundova, Dilara¹ (AUTHOR); Jeker, Barbara¹ (AUTHOR)

Source: Cancers. Jan2023, Vol. 15 Issue 2, p430. 14p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Ixazomib-associated cardiovascular adverse events in multiple myeloma: a systematic review and meta-analysis.

Authors : Ling, Yiwen¹ (AUTHOR); Li, Rui² (AUTHOR); Zhong, Jiankai³ (AUTHOR)

Source: Drug & Chemical Toxicology. Jul2022, Vol. 45 Issue 4, p1443-1448. 6p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Ixazomib‐based maintenance therapy after bortezomib‐based induction in patients with multiple myeloma not undergoing transplantation: A real‐world study.

Authors : Shen, Man¹ (AUTHOR); Zhang, Jiajia¹ (AUTHOR); Tang, Ran¹ (AUTHOR)

Source: Cancer Medicine. Jun2022, Vol. 11 Issue 11, p2173-2183. 11p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Efficacy and safety of ixazomib maintenance therapy for patients with multiple myeloma: a meta-analysis.

Authors : Chen, Huixian¹ (AUTHOR); Wang, Yongjing^1,2,3 (AUTHOR) ; Shao, Chunchun⁴ (AUTHOR)

Source: Hematology. Dec 2021, Vol. 26 Issue 1, p1031-1039. 9p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

The proteasome inhibitor ixazomib targets epigenetic chromatin modification enzymes upregulated by m2c macrophage polarisation in lung cancer.

伊沙佐米治疗复发 / 难治性多发性骨髓瘤的疗效和安全性的系统评价.

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.

A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.

Assessment of prolonged proteasome inhibition through ixazomib‐based oral regimen on newly diagnosed and first‐relapsed multiple myeloma: A real‐world Chinese cohort study.

Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.

Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma.

Ixazomib-associated cardiovascular adverse events in multiple myeloma: a systematic review and meta-analysis.

Ixazomib‐based maintenance therapy after bortezomib‐based induction in patients with multiple myeloma not undergoing transplantation: A real‐world study.

Efficacy and safety of ixazomib maintenance therapy for patients with multiple myeloma: a meta-analysis.

اتصل بنا

اتبع